268 related articles for article (PubMed ID: 31141919)
1. Hepatitis E Virus Drug Development.
Kinast V; Burkard TL; Todt D; Steinmann E
Viruses; 2019 May; 11(6):. PubMed ID: 31141919
[TBL] [Abstract][Full Text] [Related]
2. Antiviral strategies for hepatitis E virus.
Debing Y; Neyts J
Antiviral Res; 2014 Feb; 102():106-18. PubMed ID: 24374149
[TBL] [Abstract][Full Text] [Related]
3. Chronic hepatitis E in a heart transplant patient: sofosbuvir and ribavirin regimen not fully effective.
Todesco E; Mazzola A; Akhavan S; Abravanel F; Poynard T; Roque-Afonso AM; Peytavin G; Marcelin AG; Calmus Y; Lecuyer L; Guillemain R; Conti F
Antivir Ther; 2018; 23(5):463-465. PubMed ID: 29504509
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis E: when to treat and how to treat.
Abbas Z; Afzal R
Antivir Ther; 2014; 19(2):125-31. PubMed ID: 24192696
[TBL] [Abstract][Full Text] [Related]
5. Treatment of chronic hepatitis E in a patient with HIV infection.
Dalton HR; Keane FE; Bendall R; Mathew J; Ijaz S
Ann Intern Med; 2011 Oct; 155(7):479-80. PubMed ID: 21969351
[TBL] [Abstract][Full Text] [Related]
6. Performance of sofosbuvir and NITD008 in extrahepatic neuronal cells against HEV.
Jagst M; Gömer A; Todt D; Steinmann E
Antiviral Res; 2024 Jul; 227():105922. PubMed ID: 38825018
[TBL] [Abstract][Full Text] [Related]
7. Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysis.
Dolatimehr F; Karimi-Sari H; Rezaee-Zavareh MS; Alavian SM; Behnava B; Gholami-Fesharaki M; Sharafi H
Daru; 2017 Apr; 25(1):11. PubMed ID: 28427463
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis E virus treatment and ribavirin therapy: viral mechanisms of nonresponse.
Todt D; Meister TL; Steinmann E
Curr Opin Virol; 2018 Oct; 32():80-87. PubMed ID: 30384328
[TBL] [Abstract][Full Text] [Related]
9. Antiviral therapy in chronic hepatitis E: a systematic review.
Peters van Ton AM; Gevers TJ; Drenth JP
J Viral Hepat; 2015 Dec; 22(12):965-73. PubMed ID: 25760481
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis E, the neglected one.
Blasco-Perrin H; Abravanel F; Blasco-Baque V; Péron JM
Liver Int; 2016 Jan; 36 Suppl 1():130-4. PubMed ID: 26725910
[TBL] [Abstract][Full Text] [Related]
11. Sofosbuvir add-on to ribavirin for chronic hepatitis E in a cirrhotic liver transplant recipient: a case report.
Fraga M; Gouttenoire J; Sahli R; Chtioui H; Marcu C; Pascual M; Moradpour D; Vionnet J
BMC Gastroenterol; 2019 May; 19(1):76. PubMed ID: 31126238
[TBL] [Abstract][Full Text] [Related]
12. Identification of structurally re-engineered rocaglates as inhibitors against hepatitis E virus replication.
Praditya DF; Klöhn M; Brüggemann Y; Brown LE; Porco JA; Zhang W; Kinast V; Kirschning A; Vondran FWR; Todt D; Steinmann E
Antiviral Res; 2022 Aug; 204():105359. PubMed ID: 35728703
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.
Saab S; Gordon SC; Park H; Sulkowski M; Ahmed A; Younossi Z
Aliment Pharmacol Ther; 2014 Sep; 40(6):657-75. PubMed ID: 25065960
[TBL] [Abstract][Full Text] [Related]
14. Ribavirin therapy inhibits viral replication on patients with chronic hepatitis e virus infection.
Kamar N; Rostaing L; Abravanel F; Garrouste C; Lhomme S; Esposito L; Basse G; Cointault O; Ribes D; Nogier MB; Alric L; Peron JM; Izopet J
Gastroenterology; 2010 Nov; 139(5):1612-8. PubMed ID: 20708006
[TBL] [Abstract][Full Text] [Related]
15. Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study.
Terrier B; Lapidus N; Pol S; Serfaty L; Ratziu V; Asselah T; Thibault V; Souberbielle JC; Carrat F; Cacoub P
World J Gastroenterol; 2015 May; 21(18):5647-53. PubMed ID: 25987791
[TBL] [Abstract][Full Text] [Related]
16. Sofosbuvir Inhibits Hepatitis E Virus Replication In Vitro and Results in an Additive Effect When Combined With Ribavirin.
Dao Thi VL; Debing Y; Wu X; Rice CM; Neyts J; Moradpour D; Gouttenoire J
Gastroenterology; 2016 Jan; 150(1):82-85.e4. PubMed ID: 26408347
[TBL] [Abstract][Full Text] [Related]
17. Antiviral Candidates for Treating Hepatitis E Virus Infection.
Netzler NE; Enosi Tuipulotu D; Vasudevan SG; Mackenzie JM; White PA
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30885901
[TBL] [Abstract][Full Text] [Related]
18. Treatment of hepatitis E virus.
Dalton HR; Kamar N
Curr Opin Infect Dis; 2016 Dec; 29(6):639-644. PubMed ID: 27607911
[TBL] [Abstract][Full Text] [Related]
19. Mutagenic Effects of Ribavirin on Hepatitis E Virus-Viral Extinction versus Selection of Fitness-Enhancing Mutations.
Todt D; Walter S; Brown RJ; Steinmann E
Viruses; 2016 Oct; 8(10):. PubMed ID: 27754363
[TBL] [Abstract][Full Text] [Related]
20. Chronic Hepatitis E Viral Infection After Liver Transplantation: A Regression of Fibrosis After Antiviral Therapy.
Mazzola A; Tran Minh M; Charlotte F; Hdiji A; Bernard D; Wendum D; Calmus Y; Conti F
Transplantation; 2017 Sep; 101(9):2083-2087. PubMed ID: 28376032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
